Moderna and Merck have announced successful results from the final phase of clinical trials for their jointly developed cancer vaccine. Preliminary data indicates that the vaccine has demonstrated significant efficacy in treating the disease.
Following these positive findings, the companies are preparing to submit formal applications for regulatory approval to use the vaccine in cancer treatment protocols.

